Clinical Trial Update: Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) [Phase 3]

View source ↗

Summary

Phase 3 trial CheckMate 9NA/ECHO-310 evaluating nivolumab plus epacadostat with chemotherapy versus EXTREME in squamous cell carcinoma of the head and neck was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• EXTREME regimen
• Epacadostat (epacadostat)
• nivolumab (nivolumab)

Snippet

Sponsor: Incyte Corporation | Conditions: Head and Neck Cancer | Phase 3 | Status: WITHDRAWN